BH_NonClinical_Pharmacy_Car-T
This is a contract result notice, not an open opportunity. Details from the official award data.
The procurement contact named on the official notice.
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.
The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products At the time of writing it is only offered at 8 sites across the UK.
The proposed contract is for 5 years with the option to extend by up to a further 5 years.
The contract does not commit the Trust to place a minimum or any Order.
The price paid to the supplier with be capped at NICE / NHS England approved list prices.
What the notice asks for
The proposed contractor, Bristol Myers Squibb,
The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products.
Sentences from the notice that state an obligation, surfaced automatically and shown in the order they appear. Not an exhaustive list — always confirm against the tender documents.
Make the case to bid
Reveal who to approach at Barts Health NHS Trust, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- ocds-h6vhtk-05e8d3
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 077086-2025
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Barts Health NHS Trust’s tender network